MNG449
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.615
- MYC_TARGETS_V1+0.534
- E2F_TARGETS+0.509
- DNA_REPAIR+0.480
- OXIDATIVE_PHOSPHORYLATION+0.448
- G2M_CHECKPOINT+0.447
- UNFOLDED_PROTEIN_RESPONSE+0.404
- PROTEIN_SECRETION+0.396
- MTORC1_SIGNALING+0.376
- MITOTIC_SPINDLE+0.272
Top 10 suppressed
- APICAL_SURFACE-0.472
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.439
- ANGIOGENESIS-0.365
- ALLOGRAFT_REJECTION-0.363
- INTERFERON_GAMMA_RESPONSE-0.346
- PANCREAS_BETA_CELLS-0.332
- COAGULATION-0.324
- KRAS_SIGNALING_DN-0.321
- HEDGEHOG_SIGNALING-0.313
- INFLAMMATORY_RESPONSE-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_G23JJAZY | Supratentorial Ependymoma | — | 0.909 |
| 2 | MNG1063 | — | — | 0.904 |
| 3 | R143 | — | — | 0.903 |
| 4 | BS_G23JJAZY | EPN | Supratentorial EPN | 0.893 |
| 5 | e332b15a-f2dc-4282-9f33-2c87dea834b1 | — | — | 0.893 |
| 6 | TCGA-AN-A0AK-01A-21R-A00Z-07 | — | C | 0.892 |
| 7 | TCGA-46-3768-01A-01R-0980-07 | — | cohortSQ2 | 0.885 |
| 8 | cabd9320-506a-4695-a18a-7c8602633f90 | — | — | 0.883 |
| 9 | 1764b9ab-4f37-47c5-8225-40c574433f40 | — | — | 0.882 |
| 10 | c6e243ee-b2d9-408e-ac05-ccbcffa805ab | — | — | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.615 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.534 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.509 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.480 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.448 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.447 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.404 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.396 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.376 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.272 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.268 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.267 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.216 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.196 | Inavolisib | — uncovered |
| PEROXISOME | 0.189 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.152 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.088 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.074 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.071 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.065 | Inavolisib | — uncovered |